GLUE vs NRIX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NRIX is the larger of the two ($1.43B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 1.78). GLUE is the smaller challenger ($745.13M), also expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, NRIX fits (beta 1.78). If you want the steadier ride, GLUE fits (beta 1.38).

GLUE vs NRIX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricGLUENRIXWhat it tells you
Market cap$745.13M$1.43BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-5.00-10.24Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.381.78Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range1% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.501.47How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how GLUE and NRIX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GLUE and NRIX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GLUE and NRIX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Monte Rosa Therapeutics (GLUE) do?

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), small molecules that recruit the cell's natural ubiquitin-proteasome system to selectively eliminate target proteins that are otherwise hard to drug. Its QuEEN discovery engine pairs AI-guided chemistry with structural biology and proteomics to design these degraders. The pipeline centers on three programs: MRT-6160 (a VAV1-directed degrader for immune-mediated diseases, licensed to Novartis), MRT-8102 (a NEK7/NLRP3-pathway degrader for inflammatory and cardiovascular disease that posted positive interim Phase 1 data in January 2026 and full GFORCE-1 Phase 1 results in October 2026), and MRT-2359 (a MYC-pathway degrader in oncology).

Full GLUE guide

What does Nurix Therapeutics (NRIX) do?

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a registrational Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study, comparing it with pirtobrutinib in about 620 patients, that enrolled its first patient by October 2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.

Full NRIX guide

GLUE vs NRIX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • GLUE drivers: Novartis partnerships; MRT-8102 in inflammation and cardiovascular disease.
  • NRIX drivers: Bexobrutideg registrational path; Roche collaboration.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. For NRIX, as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials.

GLUE or NRIX: which should you pick?

If the story you believe is GLUE's (Novartis partnerships), GLUE is the more direct way to own it; if it is NRIX's (Bexobrutideg registrational path), NRIX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GLUE and NRIX guides.

GLUE vs NRIX: the full fundamentals

GLUE. Revenue is collaboration and license income (largely Novartis-related), not product sales, and it varies with deal timing; the October 2026 $37.5 million Novartis milestone falls after the September figures. Standard valuation multiples like P/E do not apply to a pre-profit biotech; with cash near $583 million against a market value around $744 million, the market is pricing relatively little platform value. The average target from eight analysts is about $25, roughly three times the November 20 close.

NRIX. Nurix's trailing P/E of about 5x is an artifact of one quarter: the Roche upfront payment produced roughly $550 million of net income in the August 2026 quarter, and analysts expect losses to resume in fiscal 2027. The market still values it on pipeline potential, partnership economics, and cash runway. With about $1.1 billion of cash against a market value near $1.4 billion after the Sanofi-driven selloff, investors are now assigning only about $0.3 billion to bexobrutideg and the rest of the pipeline, which is funded into the second half of 2029; dilution risk has eased while clinical risk remains. The 14 analysts Yahoo Finance tracks carry a mean target near $33.50, though several were set before the Sanofi news.

Headline figures (approximate, November 2026): GLUE shows market cap ~$744M, share price ~$8.71 (down ~43% YTD), revenue (ttm) ~$70M (collaboration income), net loss (ttm) ~-$131M; NRIX shows revenue (q3 fy2026, quarter ended aug 31 2026) ~$673.1 million (~$653.2 million Roche license revenue), net income (q3 fy2026) ~$549.8 million (~$4.73 per share vs ~$5.02 consensus), revenue (ttm) ~$702 million, net income (ttm) ~$295 million.

The bottom line: GLUE vs NRIX

GLUE and NRIX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GLUE and NRIX exposure against your real portfolio. It is not an investment adviser.

Wondering how GLUE or NRIX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Monte Rosa Therapeutics

Ask Walnut's AI anything about GLUE and see how it fits what you own.

FAQ

What is the difference between GLUE and NRIX?

+

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), small molecules that recruit the cell's natural ubiquitin-proteasome system to selectively eliminate target proteins that are otherwise hard to drug. Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is GLUE or NRIX the better stock?

+

Neither is universally better. NRIX is the larger incumbent; GLUE is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, GLUE or NRIX?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both GLUE and NRIX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of GLUE vs NRIX?

+

GLUE: Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. Molecular glue degraders remain a relatively young modality, and early positive biomarker data (such as CRP reductions) do not guarantee later-stage clinical or regulatory success. Much of the company's headline value comes from Novartis milestone potential that is contingent and may never be earned. The stock is volatile and can move sharply on single data points, and future capital raises could dilute shareholders. Competition in targeted protein degradation is intensifying across both large pharma and specialized biotechs. The shares fell about 40% over the three months to November 20, 2026 and about 20% in the past month, to near their 52-week low of about $8.63, even after the positive GFORCE-1 readout and two Novartis milestones, showing how sentiment can move independently of reported biomarker data. Partner income is lumpy: the third-quarter profit came almost entirely from a single $50 million milestone, and analysts expect revenue of under $4 million in the first quarter of 2027. NRIX: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. The roughly $1.1 billion cash position eases near-term funding pressure. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected registrational path could sharply reduce the valuation. Partner risk is real, as November 2026 showed: Sanofi's decision to end SAR448272 cut about $455 million of potential milestones and sent the shares down about 38% in a day, and Wells Fargo said it had attributed about $400 million of value to the program. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and remaining milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GLUE or NRIX; figures are approximate and dated (as of November 2026). Verify current data before investing.